Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...
A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...
Intellia Therapeutics’ in vivo CRISPR therapy, lonvo-z, met its primary goal in a Phase III hereditary angioedema trial, cutting attacks by 87% versus placebo. All treated patients avoided long-term ...
Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with ...
Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that ...
Intellia Therapeutics will seek U.S. approval for its in vivo CRISPR therapy lonvo-z after a Phase III trial in hereditary angioedema showed an 87% reduction in attacks versus placebo. The one-time ...
Nicole and Kyle Muldoon with their child, KJ, who received a CRISPR gene editing therapy at Children's Hospital of Philadelphia. From the San Francisco Business Times. Months after helping manufacture ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results